UK Pilot Subscription Model Selects Novel Antibiotic

摘要

The UK's National Institute for Health and Care Excellence（NICE)and the National Health Service England and Improvement（NHSE&l)has selected Shionogi's novel antibiotic Fetcroja（cefiderocol)to be included in a pilot subscription reimbursement model.The model aims to'de-link'payment for antibiotics from volume of use and instead base the value of any new antibiotic treatment on a health technology assessment of their benefit to the NHS.Fetcroja is indicated for the treatment of infections due to aerobic Gram-negative bacteria in adults with limited treatment options,including infections caused by carbapenem-resistant Enterobacterales and non-fermenting species such as P.aeruginosa,A.baumannii and S.maltophilia.